Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

A second study – KINGFISHER – compared monthly injections with Beovu to Eylea, and found the rate of IOI was a little higher with Novartis drug, at 4% versus 2.9% with Eylea, with most cases ...

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

This is in combination with standard-of-care anti-VEGF-A therapies (Lucentis or Eylea) compared to standard-of-care alone.